Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 204 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Papilloma Virus Vaccine Clear all
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

NCT05232851
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

NCT04084951
View directory record Official record
Conditions
Adult Solid Tumor
Interventions
SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Biological · Drug
Lead sponsor
SQZ Biotechnologies
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Sep 30, 2026, 5:58 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine

NCT04611022
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
HPV Educational Intervention
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 30, 2026, 5:58 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205
View directory record Official record
Conditions
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
BNT113, Pembrolizumab
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 30, 2026, 5:58 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination in Integrated Healthcare Delivery Systems

NCT03887793
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
VACs
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Albany, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors

NCT04469569
View directory record Official record
Conditions
Papillomavirus Vaccines
Interventions
HPV-PROTECT
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years and older
Enrollment
8,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 30, 2026, 5:58 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*

NCT07339163
View directory record Official record
Conditions
Recurrent Respiratory Papillomatosis (RRP)
Interventions
GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
Biological
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination

NCT03442062
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Assessment Feedback Incentives and eXchange, Physician-to-physician engagement, Active Intervention Control
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Albany, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer

NCT00019110
View directory record Official record
Conditions
Anal Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Penile Cancer, Vulvar Cancer
Interventions
human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
6
States / cities
Bethesda, Maryland • Boston, Massachusetts • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

NCT00604175
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent HPV vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 45 Years · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
56
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 30, 2026, 5:58 AM EDT
Terminated Not applicable Interventional

Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV)- Clinical Trial

NCT06367699
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Usual Care, ECA-HPV App with Clinic Notification and Adolescent Functions Disabled, ECA-HPV App with Clinic Notification Function Enabled, ECA-HPV App with Adolescent Function Enabled, ECA-HPV App with Clinic Notification and Adolescent Functions Enabled
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
8 Years to 12 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving HPV Vaccination Rates Among Rural and Native American Adolescents

NCT03801603
View directory record Official record
Conditions
HPV Vaccinations
Interventions
HPV vaccination training and education
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
11 Years to 17 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women

NCT01461096
View directory record Official record
Conditions
HIV Infections
Interventions
Quadrivalent HPV Vaccine, Placebo Vaccine for Male Participants Only, Placebo Vaccine for Female Participants Only
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
27 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 30, 2026, 5:58 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

"Facts Tell… and With Stories Sell?" Combining Viewer-tailored Personal Human Papillomavirus (HPV) Narrative Video With HPV Vaccine Information Video to Improve HPV Vaccine Uptake

NCT06587243
View directory record Official record
Conditions
Vaccination
Interventions
Informational Animation Video, Personal Narrative Video
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Not listed
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Alternate Dosing Schedules Study for HPV Vaccine

NCT00862810
View directory record Official record
Conditions
Cervical Cancer, Genital Warts
Interventions
Received HPV vaccine first, Received concomitant vaccines first
Biological
Lead sponsor
Duke University
Other
Eligibility
9 Years to 18 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 30, 2026, 5:58 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

NCT05996523
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma (SCC)
Interventions
PRGN-2009, Pembrolizumab, EKG, CT, PET scan, MRI, Biopsy
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 30, 2026, 5:58 AM EDT
Withdrawn Early Phase 1 Interventional

Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis

NCT00829608
View directory record Official record
Conditions
Recurrent Respiratory Papillomatosis
Interventions
Human Papillomavirus Vaccine
Biological
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer

NCT00003977
View directory record Official record
Conditions
Cervical Cancer
Interventions
human papillomavirus 16 E7 peptide, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Not applicable Interventional

Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County

NCT02067507
View directory record Official record
Conditions
Human Papilloma Virus Infection
Interventions
Tailored education and referral, Staff training and patient reminders, Clinic-level reminder systems
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
9 Years to 70 Years
Enrollment
53,414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Alhambra, California • San Fernando, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Sep 30, 2026, 5:58 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Intradermal, Fractional Dose of HPV Vaccines:

NCT04235257
View directory record Official record
Conditions
HPV Infection, HPV Vaccine
Interventions
HPV vaccine
Biological
Lead sponsor
University of Washington
Other
Eligibility
27 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Virtual Immersive Communication Training on Recommending Immunizations

NCT04368455
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Virtual Immersive Communication Training on Recommending Immunizations (VICTORI), HPV Same Way Same Day App
Behavioral
Lead sponsor
Brittany Rosen
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The STOP-HPV Trial 1: Communication Intervention

NCT03599557
View directory record Official record
Conditions
Immunization, Vaccination
Interventions
STOP-HPV communication intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Itasca, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Sep 30, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PreTeenVax Evaluation

NCT03186430
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Comprehensive Vaccine Promotion Package
Behavioral
Lead sponsor
Emory University
Other
Eligibility
11 Years to 12 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
6
States / cities
Canton, Georgia • Duluth, Georgia • Lawrenceville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 30, 2026, 5:58 AM EDT